Author

Mark Osterman 1

1 University of Pennsylvania,Philadelphia,United States

Combined ileal biomarkers can discriminate responders from non-responders to vedolizumab therapy in Crohn's disease

Mark Osterman, Elisabeth M. Davis, Ilyssa O. Gordon, Kate Simpson, Matthew A. Ciorba, Sarach C. Glover, Bincy P. Abraham, Eric Yee,, Felicia Allard, Brian Claggett, Bo Shen, Thaddeus S. Stappenbeck, Julia Liu

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY

Jean-Frederic Colombel, Walter Reinisch, Mark T. Osterman, Andrew J. Thorpe, Chudy I. Nduaka, Haiying Zhang, Nervin Lawendy, Gary S. Friedman, Chinyu Su

PREDICTING CLINICAL RESPONSE TO VEDOLIZUMAB THERAPY IN CROHN'S DISEASE WITH MUCOSAL BIOMARKER OF INNATE IMMUNE ACTIVATION

Mark T. Osterman, Ilyssa O. Gordon, Matthew A. Ciorba, Sarah C. Glover, Bincy P. Abraham, Elisabeth M. Davis, Freeha Khan, Kennedy Young, Xueyan Guo, Eric U Yee, Felicia Allard, Brian Claggett, Bo Shen, Julia Liu

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Niels Vande Casteele, William Sandborn, Brian G. Feagan, Severine Vermeire, Parambir Dulai, Julian Panés, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark Osterman, Dirk Lindner, Christian Agboton, Maria Rosario, Teresa Osborn

REAL-WORLD HEALTHCARE UTILISATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE NEWLY TREATED WITH VEDOLIZUMAB AND ANTI-TUMOUR NECROSIS FACTOR AGENTS

Mark T. Osterman

REAL-WORLD HEALTHCARE UTILISATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE NEWLY TREATED WITH VEDOLIZUMAB AND ANTI-TUMOUR NECROSIS FACTOR AGENTS

Mark T. Osterman, Anita Afzali, Xue Song, Nianwen Shi, Martha Skup, Wan-Ju Lee

Item 1 - 6 / 6
1